{"id":"https://openalex.org/W4310126154","doi":"https://doi.org/10.1182/blood-2022-165936","title":"Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia","display_name":"Functional Anti-Apoptotic Protein Dependence and Its Relation to Genomic Prognostic Markers and Response to Treatment in Chronic Lymphocytic Leukemia","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310126154","doi":"https://doi.org/10.1182/blood-2022-165936"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-165936","doi":"https://doi.org/10.1182/blood-2022-165936","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-165936","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063159222","display_name":"Stephen Jun Fei Chong","orcid":"https://orcid.org/0000-0002-9188-7131","observed_orcids":["https://orcid.org/0000-0002-9188-7131"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Jun Fei Chong","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077710470","display_name":"Junyan Lu","orcid":"https://orcid.org/0000-0002-9211-0746","observed_orcids":["https://orcid.org/0000-0002-9211-0746"]},"institutions":[{"id":"https://openalex.org/I223822909","display_name":"Heidelberg University","ror":"https://ror.org/038t36y30","country_code":"DE","type":"education","lineage":["https://openalex.org/I223822909"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Junyan Lu","raw_affiliation_strings":["2Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany","institution_ids":["https://openalex.org/I223822909"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000327956","display_name":"Rebecca Valentin","orcid":"https://orcid.org/0000-0001-8339-0902","observed_orcids":["https://orcid.org/0000-0001-8339-0902"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rebecca Valentin","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031364871","display_name":"Timothy Z. Lehmberg","orcid":"https://orcid.org/0000-0002-3259-8014","observed_orcids":["https://orcid.org/0000-0002-3259-8014"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy Z. Lehmberg","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038876039","display_name":"Mary C. Collins","orcid":"https://orcid.org/0000-0003-4282-9020","observed_orcids":["https://orcid.org/0000-0003-4282-9020"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary C Collins","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045486705","display_name":"Charles Herbaux","orcid":"https://orcid.org/0000-0003-4910-476X","observed_orcids":["https://orcid.org/0000-0003-4910-476X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Herbaux","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057884204","display_name":"Carsten Utoft Niemann","orcid":"https://orcid.org/0000-0001-9880-5242","observed_orcids":["https://orcid.org/0000-0001-9880-5242"]},"institutions":[{"id":"https://openalex.org/I2802567020","display_name":"Copenhagen University Hospital","ror":"https://ror.org/05bpbnx46","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020"]},{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Carsten Utoft Niemann","raw_affiliation_strings":["3Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2802567020","https://openalex.org/I2802709434"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029601108","display_name":"Wolfgang K. Huber","orcid":"https://orcid.org/0000-0002-0474-2218","observed_orcids":["https://orcid.org/0000-0002-0474-2218"]},"institutions":[{"id":"https://openalex.org/I4210138560","display_name":"European Molecular Biology Laboratory","ror":"https://ror.org/03mstc592","country_code":"DE","type":"government","lineage":["https://openalex.org/I4210138560"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Wolfgang Huber","raw_affiliation_strings":["4EMBL, Heidelberg, DEU"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4EMBL, Heidelberg, DEU","institution_ids":["https://openalex.org/I4210138560"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000098098","display_name":"Thorsten Zenz","orcid":"https://orcid.org/0000-0001-7890-9845","observed_orcids":["https://orcid.org/0000-0001-7890-9845"]},"institutions":[{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Thorsten Zenz","raw_affiliation_strings":["5Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210100468"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.24635423,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"4119","last_page":"4120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/bh3-profiling","display_name":"BH3 profiling","score":0.9869999885559082},{"id":"https://openalex.org/keywords/bcl-2-dependence","display_name":"BCL-2 dependence","score":0.8920000195503235},{"id":"https://openalex.org/keywords/ighv-mutation-status","display_name":"IGHV mutation status","score":0.6980000138282776},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":0.8429999947547913},{"id":"https://openalex.org/keywords/trisomy-12","display_name":"trisomy 12","score":0.9079999923706055},{"id":"https://openalex.org/keywords/17p-deletion","display_name":"17p deletion","score":0.984000027179718},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7170000076293945},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.7080000042915344},{"id":"https://openalex.org/keywords/navitoclax","display_name":"navitoclax","score":0.8090000152587891},{"id":"https://openalex.org/keywords/nutlin-3","display_name":"Nutlin-3","score":0.8840000033378601},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.5870000123977661},{"id":"https://openalex.org/keywords/multi-omics","display_name":"multi-omics","score":0.4729999899864197}],"concepts":[{"id":"https://openalex.org/C2777609679","wikidata":"https://www.wikidata.org/wiki/Q5971015","display_name":"IGHV@","level":4,"score":0.7898603677749634},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.6999039649963379},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6430062055587769},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5899994373321533},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.5770983099937439},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.49951863288879395},{"id":"https://openalex.org/C2779176958","wikidata":"https://www.wikidata.org/wiki/Q18028939","display_name":"MCL1","level":4,"score":0.41647469997406006},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4136936664581299},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4034351110458374},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.39506101608276367},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3132810592651367},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.18921101093292236},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.1322249472141266},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.10949563980102539}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-165936","doi":"https://doi.org/10.1182/blood-2022-165936","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-165936","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4408082405","https://openalex.org/W4310096553","https://openalex.org/W4405044417","https://openalex.org/W2097290512","https://openalex.org/W3097747854","https://openalex.org/W2586728717","https://openalex.org/W1123756285","https://openalex.org/W2338236654","https://openalex.org/W2549901554","https://openalex.org/W1902771827"],"abstract_inverted_index":{"Introduction":[0],"Due":[1],"to":[2,43,70,76,85,108,114,121,132,335,378,428,438],"its":[3],"heterogenous":[4],"biology,":[5],"chronic":[6],"lymphocytic":[7],"leukemia":[8],"(CLL)":[9],"is":[10,66,300,337],"a":[11,29,67,204],"well-suited":[12],"disease":[13],"for":[14,23,95,416,451],"identifying":[15],"new":[16],"relationships":[17],"between":[18,163,293],"genomic":[19],"and":[20,32,47,99,104,117,125,128,136,155,167,176,192,278,295,323,360,418,446],"functional":[21,38,68,432],"biomarkers":[22],"drug":[24,48,190,228,383],"response.":[25],"Here,":[26],"we":[27,223,374],"combined":[28],"multi-omics":[30],"approach":[31,435],"ex":[33,213,257,307],"vivo":[34,214,258,308,382,426],"drug-treatment":[35],"data":[36],"with":[37,50,200,216,234,260,268,274,310,319,355,385,391,408,441,453],"characterization":[39,399],"of":[40,74,219,400],"apoptotic":[41,401],"sensitivity":[42,49,231,334,427],"correlate":[44],"genetic":[45,168,444],"features":[46,169],"specific":[51,87,161,227],"anti-apoptotic":[52,88,164,235],"signaling":[53,402],"patterns":[54,232],"measured":[55,187],"by":[56,188],"BH3":[57,64,97,157,195,376,420],"profiling":[58,65,158,377,421],"in":[59,208,381,403,425,456],"primary":[60,149],"CLL":[61,150,209,241,303,348,404,442],"samples.":[62],"Methods":[63],"assay":[69],"measure":[71],"the":[72,90,160,261,290,311,345],"proximity":[73,113],"cells":[75,91],"undergo":[77],"apoptosis":[78],"via":[79],"overall":[80,110],"priming":[81,111],"as":[82,84,102,171,186,238,240,283,285],"well":[83,239,284],"identify":[86,109,122,133],"proteins":[89],"are":[92,197,411],"dependent":[93,339,413],"on":[94,340,351,414],"survival.":[96],"peptides":[98],"mimetic":[100],"such":[101],"BIM":[103],"PUMA":[105],"were":[106,119,130],"used":[107,120,131],"or":[112,230,297],"apoptosis,":[115],"BAD":[116,193],"ABT199":[118,189],"BCL-2":[123,184,320,330,341,352,371,387,415,429],"dependence,":[124,185,327,331],"FS1,":[126],"MS1":[127],"HRK":[129],"BFL-1,":[134],"MCL-1":[135],"BCL-xL":[137,279,298,324],"dependences":[138],"respectively":[139],"(Ryan":[140],"et":[141],"al,":[142],"Biol":[143],"Chem,":[144],"2016).":[145],"Results":[146],"We":[147],"analyzed":[148],"samples":[151],"from":[152],"73":[153],"patients":[154,407,440],"using":[156],"identified":[159,225],"associations":[162],"protein":[165,236],"dependence":[166,237,282,299,350,388],"(such":[170],"IGHV":[172,202,410],"status,":[173,203],"trisomy-12,":[174],"del(17p)":[175],"TP53":[177,269],"mutation.":[178],"Our":[179],"univariate":[180],"models":[181,250],"demonstrated":[182,253,405],"that":[183,254,333,367,406,419],"(p=0.001)":[191],"(p=0.004)":[194],"peptide,":[196],"highly":[198,338],"correlated":[199,267,273,318,354],"mutated":[201,409],"favorable":[205],"prognostic":[206,242],"marker":[207],"(Figure":[210,244,287,342],"1A).":[211],"Using":[212],"treatment":[215,259,309],"multiple":[217],"classes":[218],"small":[220],"molecule":[221],"inhibitors,":[222],"further":[224,449],"several":[226],"response":[229],"correlating":[233,390],"factors":[243],"1B).":[245,343],"In":[246],"particular,":[247],"our":[248],"multivariate":[249],"(LASSO":[251],"regularized)":[252],"viability":[255,305],"following":[256,306],"MDM-2":[262],"inhibitor":[263,314],"Nutlin-3":[264,294],"was":[265,316],"positively":[266,353],"mutation/deletion,":[270],"but":[271],"inversely":[272],"BFL-1":[275,296],"(FS1":[276],"peptide)":[277,281,322,326],"(HRK":[280,325],"trisomy-12":[286],"1B),":[288],"though":[289,328],"inverse":[291],"correlation":[292,452],"relatively":[301],"weak.":[302],"cell":[304,349],"dual":[312],"BCL-2/BCL-xL":[313],"navitoclax":[315,336],"negatively":[317],"(BAD":[321],"primarily":[329],"suggesting":[332],"At":[344],"transcriptomic":[346],"level,":[347,364],"NOXA":[356],"expression,":[357],"NF\u03baB":[358],"signaling,":[359],"reduced":[361],"intracellular":[362],"oxidative":[363],"various":[365],"pathways":[366],"could":[368,422],"potentially":[369],"maintain":[370],"dependence.":[372],"Finally,":[373],"utilized":[375],"retrospectively":[379,423],"predict":[380,424],"response,":[384],"high":[386],"(p=0.016)":[389],"greater":[392],"absolute":[393],"lymphocyte":[394],"count":[395],"decrease.":[396],"Conclusion":[397],"Functional":[398],"more":[412],"survival,":[417],"inhibition.":[430],"This":[431],"precision":[433],"medicine":[434],"may":[436],"help":[437],"stratify":[439],"beyond":[443],"markers":[445],"should":[447],"be":[448],"explored":[450],"clinical":[454,458],"outcomes":[455],"prospective":[457],"trials.":[459],"Figure":[460],"1View":[461,464],"largeDownload":[462,465],"PPTFigure":[463],"PPT":[466],"Close":[467],"modal":[468]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}